You are here

A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis

Last updated on February 17, 2019

FOR MORE INFORMATION
Study Location
Bioskin GmbH
Hamburg, , 20095 Germany
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis Vulgaris
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy male and/or female subjects age 18 years and older, inclusive. Healthy is
defined as no clinically relevant abnormalities identified by a detailed medical
history, full physical examination, including blood pressure and pulse rate
measurement, 12 lead ECG or clinical laboratory tests.

- Subjects with psoriasis vulgaris in a chronic stable phase and with a plaque area of
mild to moderate severity sufficient for six treatment fields located in up to three
plaque areas.

- The target lesion(s) should be on the trunk or extremities (excluding palms/soles).
Psoriatic lesions on the knees or elbows are not to be used as a target lesion.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects with psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica,
psoriasis arthropathica and pustular psoriasis.

- Treatment with any systemic medications which in the opinion of the investigator might
counter or influence the trial aim (including anti psoriasis medications, eg,
corticosteroids, cytostatics or retinoids) or medications which are known to provoke
or aggravate psoriasis (eg, beta blocker, anti malarial drugs, lithium) or
phototherapy/psoralen+UVA (PUVA) within 4 weeks preceding the treatment phase of the
trial and during the trial.

- Treatment with any locally acting medications (including anti-psoriasis medications
like vitamin D analogues, dithranol) within 4 weeks of the treatment phase.

NCT02193815
Pfizer
Completed
A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Psoriasis Vulgaris
NCT02193815
All Genders
18+
Years
Hamburg,
Psoriasis Vulgaris, Psoriasis
NCT01831466
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now